Table 2.
Plasma treatment (PG) and propensity-matched non-plasma treatment control group (CG) analysis.
| Characteristic | CG |
PG |
Relative risk or median (mean) difference (95% CI) | p | ||
|---|---|---|---|---|---|---|
| n | Level | n | Level | |||
| Deaths, n (%) | 102 | 35 (34.3) | 102 | 14 (13.7) | 2.50 (1.43, 4.36)2 | 0.001 |
| Ventilator, n (%) | 102 | 22 (21.6) | 102 | 12 (11.8) | 1.83 (0.96, 3.50)2 | 0.060 |
| Intensive care stay, n (%) | 102 | 25 (24.5) | 102 | 23 (22.5) | 1.09 (0.66, 1.78) 2 | 0.741 |
| Ventilator time, days, median (range) | 22 | 6.00 (1.00, 29.00) | 12 | 8.00 (1.00, 28.00) | −2.00 (-6.00, 4.00)1 | 0.701 |
| Hospitalization time, days, median (range) | 101 | 13.00 (0.00, 59.00) | 101 | 20.00 (0.00, 63.00) | −7.00 (-10.00, -5.00)1 | <0.001 |
| SARS-CoV-2 elimination time, days, mean (SD) | 64 | 18.63 (10.39) | 82 | 22.22 (11.50) | −3.59 (-7.23, 0.04)1 | 0.053 |
| Use of corticosteroids, n (%) | 102 | 11 (10.8) | 102 | 27 (26.5) | 0.41 (0.21;0.77) | 0.007 |
Groups were compared with a chi-square test for dichotomous variables and a t-test (elimination time) or Mann-Whitney U test (ventilator time, hospitalization time) for continuous variables, depending on distribution normality. Mean or median differences between groups were calculated as non-plasma group minus plasma group with 95% confidence interval for continuous variables, a relative risk with 95% confidence interval was calculated for nominal variables.